Infliximab biosimilar-induced lupus nephritis: A case report.
Kenta ShidaharaTakayuki KatsuyamaKei HiroseKazuya MatsumotoShoichi NawachiTakato NakadoiYosuke AsanoYu KatayamaYoshia MiyawakiEri KatsuyamaMariko Takano-NarazakiYoshinori MatsumotoKen-Ei SadaJun WadaPublished in: Modern rheumatology case reports (2023)
We present a case of microhematuria, proteinuria and hypocomplementemia that developed in a 55-year-old female who was being treated with an infliximab biosimilar (IFX-BS) for rheumatoid arthritis (RA). Renal biopsy showed lupus nephritis (ISN/RPS classification class IV+V). Treatment with the IFX-BS was discontinued, and treatment with prednisolone, hydroxychloroquine and abatacept was started, resulting in clinical remission of lupus nephritis and RA. Although tumor necrosis factor-α (TNF-α) inhibitors are known to induce production of autoantibodies, symptoms are usually limited to skin involvement or arthritis, and renal complications are rare. Physicians should be aware of the risk of lupus nephritis and carefully monitor patients for the development of renal involvement during treatment with TNF-α inhibitors.
Keyphrases
- rheumatoid arthritis
- disease activity
- ankylosing spondylitis
- interstitial lung disease
- end stage renal disease
- newly diagnosed
- systemic lupus erythematosus
- rheumatoid arthritis patients
- primary care
- ulcerative colitis
- chronic kidney disease
- machine learning
- deep learning
- oxidative stress
- prognostic factors
- combination therapy
- diabetic rats
- systemic sclerosis